Harvard-linked Sana Biotechnology will raise as much as $397m if it floats at the upper end and underwriters take up the greenshoe option.
Sana Biotechnology, a US-based stem cell medicines developer based on research at Harvard University, has set its price range at $20 to $23 and plans to issue 15 million shares in its IPO on the Nasdaq Global Select Market.
The company has also allocated an additional 2.5 million shares to the overallotment option. It stands to receive proceeds in between $300m at the lower end and, if underwriters take up the greenshoe option in full, as much as…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
